Company Encyclopedia
View More
name
Rani Therapeutics
RANI.US
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions.
4.080 T
RANI.USMarket value -Rank by Market Cap -/-

Financial Score

10/11/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking143/177
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE1194.73%A
    • Profit Margin-2359.58%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY0.00%C
    • Net Profit YoY-0.52%C
    • Total Assets YoY-76.71%E
    • Net Assets YoY-307.32%E
  • Cash ScoreD
    • Cash Flow Margin-4.24%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreE
    • Gearing Ratio218.09%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Rani Therapeutics (NASDAQ:RANI) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

    Rani Therapeutics (NASDAQ:RANI) reported quarterly earnings of ($0.12) EPS, missing estimates of ($0.09) by $0.03. The stock fell to $2.02, with a market cap of $145.18 million. Major shareholder South Cone Investments sold 4 million shares, while Director Mir A. Imran purchased 2.08 million shares. Institutional ownership stands at 30.19%. Analysts have mixed ratings, with a target price range from $5.00 to $11.00, reflecting a "Moderate Buy" average rating.

    Market Beat·
    US
    RANI
    -11.01%
    Market Beat·
    US
    RANI
    -11.01%

    H.C. Wainwright Sticks to Its Buy Rating for Rani Therapeutics Holdings (RANI)

    H.C. Wainwright analyst Brandon Folkes has maintained a Buy rating for Rani Therapeutics Holdings (RANI), setting a price target of $11.00. The consensus among analysts is a Strong Buy with an average price target of $10.00. Folkes has an average return of -1.2% and a success rate of 40.33%, covering the Healthcare sector.

    Tip Ranks·
    US
    RANI
    -11.01%
    Tip Ranks·
    US
    RANI
    -11.01%

    Rani Therapeutics | 8-K: FY2025 Q3 Revenue Meets Estimate at USD 0

    LB filings·
    US
    RANI
    -11.01%
    LB filings·
    US
    RANI
    -11.01%

    Rani Therapeutics Q3 net loss decreases, extends cash runway into 2028

    Rani Therapeutics reported a Q3 net loss of $7.9 million, down from $12.7 million in Q3 2024. The company completed a $60.3 million oversubscribed private placement, extending its cash runway into 2028. Rani plans to initiate a Phase 1 trial for RT-114 by the end of 2025. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $10.50, representing a 76.2% upside from its recent closing price of $2.50.

    Reuters·
    US
    RANI
    -11.01%
    Reuters·
    US
    RANI
    -11.01%

    Rani Therapeutics Holdings posts net loss of $31.9 million for Q3 2025

    Rani Therapeutics Holdings Inc. reported a net loss of $31.9 million for the nine months ended September 30, 2025, a 22% decrease from a net loss of $40.9 million in the same period of 2024. The net loss attributable to the company was $19.4 million, down 8.1% from $21.1 million the previous year. Contract revenue was $0.2 million, attributed to an agreement with Chugai, compared to no revenue in 2024. The company is focused on developing its oral delivery technology and pursuing partnerships with biopharmaceutical firms.

    Reuters·
    US
    RANI
    -11.01%
    Reuters·
    US
    RANI
    -11.01%